Sarah A. Stanley

Sarah A. Stanley

Auto-generated profile, based on publicly available information

Sarah A. Stanley

Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2019 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
SSSarah Stanley
Sarah Stanley
AMAmir Moheet
Amir Moheet
ESElizabeth R Seaquist
Elizabeth R Seaquist
Glucose homeostasis requires an organism to rapidly respond to changes in plasma glucose concentrations. Iatrogenic hypoglycemia as a result of treatment with insulin or sulfonylureas is the most common cause of hypoglycemia in humans and is generally only seen in patients with diabetes who take these medications. The first response to a fall in glucose is the detection of impending hypoglycemia by hypoglycemia-detecting sensors, including glucose-sensing neurons in the hypothalamus and other regions. This detection is then linked to a series of neural and hormonal responses that serve to prevent the fall in blood glucose and restore euglycemia. In this review, we discuss the current state of knowledge about central glucose sensing and how detection of a fall in glucose leads to the stimulation of counterregulatory hormone and behavior responses. We also review how diabetes and recurrent hypoglycemia impact glucose sensing and counterregulation, leading to development of impaired awareness of hypoglycemia in diabetes.

29 March 2022 in Diabetologia
Verified
Journal Article
Closed access
PDF file
RHRollie F. Hampton
Rollie F. Hampton
MJMaria Jimenez-Gonzalez
Maria Jimenez-Gonzalez
SSSarah A. Stanley
Sarah A. Stanley

9 October 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
AAAlexandra Alvarsson
Alexandra Alvarsson
MJMaria Jimenez-Gonzalez
Maria Jimenez-Gonzalez
RLRosemary Li
Rosemary Li
CRCarolina Rosselot
Carolina Rosselot
NTNikolaos Tzavaras
Nikolaos Tzavaras
SSSarah A. Stanley
Sarah A. Stanley
Three-dimensional mapping of pancreatic innervation shows rapid remodeling of islet innervation in mouse and human diabetes.

10 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
CRCarolina Rosselot
Carolina Rosselot
YLYansui Li
Yansui Li
PWPeng Wang
Peng Wang
AAAlexandra Alvarsson
Alexandra Alvarsson
KBKara Beliard
Kara Beliard
AGAdolfo Garcia-Ocaña
Adolfo Garcia-Ocaña
Five hundred thirty-seven million people globally suffer from diabetes. Insulin-producing β cells are reduced in number in most people with diabetes, but most individuals still have some residual β cells. However, none of the many diabetes drugs in common use increases human β cell numbers. Recently, small molecules that inhibit dual tyrosine-regulated kinase 1A (DYRK1A) have been shown to induce immunohistochemical markers of human β cell replication, and this is enhanced by drugs that stimulate the glucagon-like peptide 1 (GLP1) receptor (GLP1R) on β cells. However, it remains to be demonstrated whether these immunohistochemical findings translate into an actual increase in human β cell numbers in vivo. It is also unknown whether DYRK1A inhibitors together with GLP1R agonists (GLP1RAs) affect human β cell survival. Here, using an optimized immunolabeling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO + ) protocol in mouse kidneys bearing human islet grafts, we demonstrate that combination of a DYRK1A inhibitor with exendin-4 increases actual human β cell mass in vivo by a mean of four- to sevenfold in diabetic and nondiabetic mice over 3 months and reverses diabetes, without alteration in human α cell mass. The augmentation in human β cell mass occurred through mechanisms that included enhanced human β cell proliferation, function, and survival. The increase in human β cell survival was mediated, in part, by the islet prohormone VGF. Together, these findings demonstrate the therapeutic potential and favorable preclinical safety profile of the DYRK1A inhibitor–GLP1RA combination for diabetes treatment.

14 July 2022 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
MJM. Jimenez-Gonzalez
M. Jimenez-Gonzalez
RLR. Li
R. Li
LPL. E. Pomeranz
L. E. Pomeranz
AAA. Alvarsson
A. Alvarsson
RMRoberta Marongiu
Roberta Marongiu
SSS. A. Stanley
S. A. Stanley
A lack of comprehensive mapping of ganglionic inputs into the pancreas and of technology for the modulation of the activity of specific pancreatic nerves has hindered the study of how they regulate metabolic processes. Here we show that the pancreas-innervating neurons in sympathetic, parasympathetic and sensory ganglia can be mapped in detail by using tissue clearing and retrograde tracing (the tracing of neural connections from the synapse to the cell body), and that genetic payloads can be delivered via intrapancreatic injection to target sites in efferent pancreatic nerves in live mice through optimized adeno-associated viruses and neural-tissue-specific promoters. We also show that, in male mice, the targeted activation of parasympathetic cholinergic intrapancreatic ganglia and neurons doubled plasma-insulin levels and improved glucose tolerance, and that tolerance was impaired by stimulating pancreas-projecting sympathetic neurons. The ability to map the peripheral ganglia innervating the pancreas and to deliver transgenes to specific pancreas-projecting neurons will facilitate the examination of ganglionic inputs and the study of the roles of pancreatic efferent innervation in glucose metabolism.

3 September 2025 in Nature
Verified
Journal Article
Open access
PDF file
JCJ. R. E. Carty
J. R. E. Carty
KDK. Devarakonda
K. Devarakonda
ROR. M. O’cOnnor
R. M. O’cOnnor
AKA. Krek
A. Krek
DED. Espinoza
D. Espinoza
SSS. A. Stanley
S. A. Stanley
Behavioural adaptations to environmental threats are crucial for survival1,2 and necessitate rapid deployment of energy reserves3,4,5. The amygdala coordinates behavioural adaptations to threats6, but little is known about its involvement in underpinning metabolic adaptations. Here we show that acute stress activates medial amygdala (MeA) neurons that innervate the ventromedial hypothalamus (MeAVMH neurons), which precipitates hyperglycaemia and hypophagia. The glycaemic actions of MeAVMH neurons occur independently of adrenal or pancreatic glucoregulatory hormones. Using whole-body virus tracing, we identify a polysynaptic connection from MeA to the liver that promotes the rapid synthesis of glucose by hepatic gluconeogenesis. Repeated stress exposure disrupts MeA control of blood glucose, resulting in diabetes-like dysregulation of glucose homeostasis. Our findings reveal an amygdala–liver axis that regulates rapid glycaemic adaptations to stress and links recurrent stress to metabolic dysfunction.